NERVE AGENTS - PROPERTIES AND CLINICAL EFFECTS
Mechanism of Action
The 5 nerve agents, tabun (GA), sarin
(GB), soman (GD), cyclosarin (GF), and VX, have chemical structures
similar to the common organophosphate pesticide malathion. Like
organophosphate insecticides, these agents phosphorylate and inactivate
acetylcholinesterase (AChE). Acetylcholine accumulates at nerve terminals,
initially stimulating and then paralyzing cholinergic neurotransmission
throughout the body.
Inhibition of AChE may not account for all of the toxic effects of
nerve agents. These agents also are known to bind directly to nicotinic
receptors and cardiac muscarinic receptors. They also antagonize
gamma-aminobutyric acid (GABA) neurotransmission and stimulate glutamate
N-methyl-d-aspartate (NMDA) receptors. These latter actions may
partly mediate nerve agent–induced seizures and CNS neuropathology.
Physical Properties
Under temperate conditions, all nerve
agents are volatile liquids. The most volatile agent, sarin, evaporates at
approximately the same rate as water. The least volatile agent, VX, has
the consistency of motor oil. This persistence and higher lipophilicity
make VX 100-150 times more toxic than sarin when victims sustain dermal
exposure. A 10-mg dose applied to the skin is lethal to 50% of unprotected
individuals.
All nerve agents rapidly penetrate skin and clothing. Nerve agent
vapors are heavier than air and tend to sink into low places (eg,
trenches, basements).
Clinical Effects
Nerve agents produce muscarinic, nicotinic,
and direct CNS toxicity with a wide variety of effects on the respiratory
tract, cardiovascular system, CNS, gastrointestinal (GI) tract, muscles,
and eyes. Onset and severity of clinical effects vary widely, since
numerous variables determine predominant effects. Agent identity, dose
(determined by concentration and duration of exposure), and type of
exposure primarily determine nerve agent toxicity. Toxic effects result
from dermal exposure to liquid and ocular and inhalation exposure to
vapor.
Liquid exposure
Liquid agents easily penetrate skin and clothing. Onset of symptoms
occurs from 30 minutes to 18 hours following dermal exposure.
Minimal liquid exposure (eg, a small droplet on the skin) may cause
local sweating and muscle fasciculation, followed by nausea, vomiting,
diarrhea, and generalized weakness. Even with decontamination, signs and
symptoms may persist for hours.
In contrast, persons with severe liquid exposures may be briefly
asymptomatic (1-30 min) but rapidly may suffer abrupt loss of
consciousness, convulsions, generalized muscular fasciculation, flaccid
paralysis, copious secretions (nose, mouth, lungs), bronchoconstriction,
apnea, and death.
Vapor exposure
Vapor inhalation produces clinical toxicity within seconds to several
minutes. Effects may be local or systemic. Exposure to even a small amount
of vapor usually results in at least one of the following categories of
complaints: (1) ocular (miosis, blurred vision, eye pain, conjunctival
injection), (2) nasal (rhinorrhea), or (3) pulmonary (bronchoconstriction,
bronchorrhea, dyspnea).
Exposure to a vapor concentration of 3.0 mg/m3 for 1 minute
causes miosis and rhinorrhea. Inhalation of a high concentration of vapor
results in loss of consciousness after only one breath, convulsions,
respiratory arrest, and death. For example, breathing 10 mg /m3
of sarin vapor for only 10 minutes (100 mg/m3 for 1 min) causes
death in approximately one half of exposed individuals. Severe vapor
exposures also are characterized by generalized fasciculations,
hypersecretions (mouth, lungs), and intense bronchoconstriction with
respiratory compromise.
Respiratory tract
Nerve agents act on the upper respiratory tract to produce profuse
watery nasal discharge, hypersalivation, and weakness of the tongue and
pharynx muscles. Laryngeal muscles are paralyzed, resulting in stridor. In
the lower respiratory tract, nerve agents produce copious bronchial
secretions and intense bronchoconstriction. If untreated, the combination
of hypersecretion, bronchoconstriction, respiratory muscle paralysis, and
CNS depression rapidly progresses to respiratory failure and death. Nerve
agents depress the central respiratory drive directly. Thus, early death
following large vapor exposure likely results from primary respiratory
arrest, not from neuromuscular blockade, bronchorrhea, or
bronchoconstriction.
Cardiovascular system
The cardiovascular effects of nerve agents vary and depend on the
balance between their nicotinic receptor–potentiating effects at autonomic
ganglia and their muscarinic receptor–potentiating effects at
parasympathetic postganglionic fibers that innervate the heart.
Sinus tachydysrhythmias with or without hypertension (sympathetic tone
predomination) or bradydysrhythmias with or without variable
atrioventricular blockade and hypotension (parasympathetic tone
predomination) may occur.
Superimposed hypoxia may produce tachycardia or precipitate ventricular
tachydysrhythmias.
Nerve agent–induced prolonged QT and torsades de pointes have been
described in animals.
In victims of the Tokyo sarin gas attack, sinus tachycardia and
hypertension were common cardiovascular abnormalities, while sinus
bradycardia was uncommon.
Central nervous system
Nerve agents produce a variety of neurologic signs and symptoms by
acting on cholinergic receptors throughout the CNS. The most important
clinical signs of neurotoxicity are a rapidly decreasing level of
consciousness (sometimes within seconds of exposure) and generalized
seizures. Symptoms such as headache, vertigo, paresthesias, anxiety,
insomnia, depression, and emotional lability also have been reported.
Musculoskeletal system
Nerve agents initially stimulate and then paralyze neurotransmission at
the neuromuscular junction. With minimal exposure, exposed persons may
complain of vague weakness or difficulty walking. More significant
exposures resemble the clinical effects that result from succinylcholine,
with initial fasciculations followed by flaccid paralysis and apnea.
Ocular
Nerve agent liquid or vapor readily penetrates the conjunctiva and
exerts direct muscarinic parasympathetic effects. This results in
constriction of the iris (miosis, blurred and dim vision, headache),
constriction of the ciliary muscle (pain, nausea, vomiting), and
stimulation of the lacrimal glands (tearing, redness). Although miosis is
the most consistent clinical finding after vapor exposure to nerve agents
(occurred in 99% of persons exposed in Tokyo sarin attack), it may be
absent or delayed in dermal exposure. Duration of miosis varies according
to the extent of ocular exposure (up to 45 d).
Laboratory Tests
Routine toxicology testing does not identify
nerve agents in serum or urine. Measurements of red blood cell (RBC) or
plasma cholinesterase activity have been used as an index of the severity
of nerve agent toxicity, but this approach is not always reliable. The
reference range of RBC cholinesterase activity may vary widely, and mild
exposures may be difficult to interpret without baseline measurement. In
addition, RBC cholinesterase activity may not correlate with the severity
of signs and symptoms following vapor exposure.
In the Tokyo subway sarin attack, 27% of patients with clinical
manifestations of moderate poisoning had plasma cholinesterase activity in
the normal range. Moreover, different organophosphates variably inhibit
RBC and plasma cholinesterase. For example, in mild-to-moderate exposures
to sarin or VX, RBC cholinesterase activity is decreased to a much greater
extent than plasma cholinesterase activity.
Since plasma cholinesterase is produced by the liver, its activity also
may be depressed in certain conditions (eg, liver disease, pregnancy,
infections) or with certain drugs (eg, oral contraceptives). Conversely, a
20-25% reduction in RBC cholinesterase activity tends to correlate with
severe clinical toxicity and, despite the exception noted above, activity
of both enzymes approaches zero in most severely poisoned victims.
Nevertheless, treatment decisions should be clinically based. Never
withhold treatment from a symptomatic patient while awaiting laboratory
confirmation. Conversely, decreased cholinesterase activity in the absence
of clinical signs of toxicity is not an indication for treatment.
MUSTARDS - MEDICAL MANAGEMENT
Personal protective
equipment
Liquid mustard contamination poses a dermal contact risk for emergency
care personnel. Specialized protective military garments containing a
charcoal layer to absorb penetrating sulfur mustard provide protection for
up to 6 hours. These protective garments (chemical protective overgarment,
battle dress overgarment, mission-oriented protective posture) are not
available outside the military. Level A PPE provides the best protection
for civilian first responders, and hospital-based emergency care personnel
involved in subsequent decontamination should wear level A PPE.
Decontamination
Decontamination within 2 minutes of exposure is the most important
intervention for patients with dermal exposure, since mustard rapidly
becomes fixed to tissues, and its effects are irreversible. The classic
description is an initial lack of signs and symptoms, which does not
lessen the urgency to decontaminate patients as soon as possible.
Remove clothing immediately and wash the underlying skin with soap and
water. Ocular exposure requires immediate copious irrigation with saline
or water. Next, decontaminate the skin with 0.5% hypochlorite solution or
with alkaline soap and water, which chemically inactivates sulfur mustard.
Because mustard is relatively insoluble in water, water alone has limited
value as a decontaminant. Decontamination after the first few minutes of
exposure does not prevent subsequent damage but at least protects
emergency care personnel from further contact exposure.
Supportive care
Treatment of mustard exposure proceeds according to symptoms. Since the
effects of mustards typically are delayed, persons with complaints
immediately after exposure may have an additional injury. Patients with
signs of upper airway obstruction require endotracheal intubation or the
creation of a surgical airway. Also consider endotracheal intubation for
persons with severe exposures. Use the largest endotracheal tube that can
pass through, since sloughing epithelium may obstruct smaller tubes. Have
patients inhale moist air. Mucolytics also are recommended for those with
respiratory complaints.
Avoid overhydration, since fluid losses generally are less than with
thermal burns. Monitor fluid and electrolyte status and replace losses
accordingly. Mustard-induced burns are especially painful, warranting the
liberal use of narcotic analgesia. Adequate burn care is essential, since
skin lesions heal slowly and are prone to infection. Severe burns may
require debridement, irrigation, and topical antibiotics, such as silver
sulfadiazine. Address tetanus toxoid immunity.
Severe ocular burns require ophthalmologic consultation. Eye care
typically includes daily irrigation, topical antibiotic solutions, topical
corticosteroids, and mydriatics. Treat minor corneal injuries similarly to
corneal abrasions. Apply petroleum jelly to prevent eyelid margins from
sticking together. More severe corneal injuries may take as long as 2-3
months to heal. Permanent visual defects are rare.
Specific therapy
Although no antidotes currently are available to treat mustard
toxicity, several agents are under investigation, including antioxidants
(vitamin E), anti-inflammatory drugs (corticosteroids), mustard scavengers
(glutathione, N-acetylcysteine), and nitric oxide synthase
inhibitors (L-nitroarginine methyl ester).
Administer granulocyte colony-stimulating factor to patients with bone
marrow suppression following mustard exposure.
Disposition
Patients with significant respiratory tract burns usually require ICU
admission and aggressive pulmonary care. Admit patients with significant
dermal burns to a burn unit for aggressive wound management, analgesia,
and supportive care. Arrange to monitor blood cell counts for 2 weeks
following significant exposures. For 12 hours prior to discharge, observe
patients who are initially asymptomatic following mustard exposure.
Most patients recover completely. Only a small fraction have chronic
ocular or pulmonary damage. Approximately 2% of those exposed to sulfur
mustard in World War I died, mostly due to burns, respiratory tract
damage, and bone marrow suppression. Sulfur mustard is a known carcinogen,
yet a single exposure causes only minimal risk.
CONCLUSION
CWAs comprise a diverse group of
extremely hazardous materials. Emergency physicians should be familiar
with the pathophysiology and various clinical presentations produced by
CWAs as well as the principles and practices of appropriate medical
management. Since deployment of CWAs also places emergency care providers
at serious risk of exposure, emergency physicians must be familiar with
PPE and decontamination.
As potential weapons of mass destruction, CWAs are capable of causing a
catastrophic medical disaster, which would overwhelm any healthcare
system. Since civilian victims exposed to CWAs are likely to flee to the
nearest hospital, emergency physicians play a key role in preparing
emergency departments for the treatment of persons exposed to CWAs.
Home page,
Drug information's
,Regional anesthesia
,Index for diseases
,Index for diseases,
Perioperative medicine,
Search engine,
Accreditation,
Learn Arabic
Warfare,
Anesthesia LINKS,
Orthopedic LINKS,
Midline
Constructed
by Dr N.A. Nematallah Consultant in perioperative medicine and intensive therapy,
Al Razi Orthopedic Hospital , State of Kuwait, email : razianesth@freeservers.com